Gilead to launch generic version of its controversially priced hepatitis C drugs

(By Alia Paavola for Becker’s Hospital Review)

Gilead Sciences will offer a cheaper version of its blockbuster hepatitis C drugs, Epclusa and Harvoni, which sparked controversy when they were initially introduced at a price of more than $1,000 per pill, according to Bloomberg. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.